BioPharma Dive - Latest News

Ozempic, Wegovy shortage resolved; Pfizer CEO is PhRMA’s new chair

The FDA determined that Novo Nordisk’s obesity and diabetes drugs were no longer in short supply. Elsewhere, Concentra made a competing bid for Acelyrin and Intra-Cellular sales rose.

Feb 21, 2025 - 17:26
 0
Ozempic, Wegovy shortage resolved; Pfizer CEO is PhRMA’s new chair

The FDA determined that Novo Nordisk’s obesity and diabetes drugs were no longer in short supply. Elsewhere, Concentra made a competing bid for Acelyrin and Intra-Cellular sales rose.

Read More

Tags:

Previous Article

MeiraGTx gene therapy allows 11 blind children to see as biotech eyes accelerate...

Next Article

The D Brief: DOD firings on hold, for now; Acquisition-policy shift; More US-Rus...

Related Posts

Novo adds to obesity drug pipeline via $200M deal with China-based biotech

Novo adds to obesity drug pipeline via $200M deal with ...

Mar 24, 2025  0

Biotech startup pulls in $187M to make ‘multi-payload’ ADCs

Biotech startup pulls in $187M to make ‘multi-payload’ ...

Mar 3, 2025  0

Makary, under review to run FDA, evades pressure to reinstate canceled vaccine meeting

Makary, under review to run FDA, evades pressure to rei...

Mar 6, 2025  0